Product Images Tadalafil

This is a statistical chart that compares the average change from the baseline distance, in meters, between a group of 82 patients given a placebo and a group of 79 patients given 40mg Tadalafil tablets. The asterisks indicate the level of statistical significance, with one (*) representing p=0.0152 and two (**) representing p=0.0084.*

This text appears to be a table and a graph showing the results of a study comparing the effects of a placebo versus tadalafl tablets on subjects with a certain condition. The table includes information on the number of subjects, their gender and age, their functional status and the results of certain measurements. The graph displays the "Placebo-adjusted Mean Change" in the "6 Minute Walk Distance" of the tadalafl tablet group over time, with confidence intervals. No further information can be provided based on this text.*

This is a medication description for Tadalafi tablets. Each tablet contains 20 mg of Tadalafi, USP. The usual dosage is to take two 20 mg tablets at a time, totaling 40 mg once a day, precisely as prescribed by a healthcare professional. The tablets must be kept away from children and put in a secure container. The dosing information is available in the accompanying literature. The tablets should be stored at a temperature of 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (58°F to 86°F), as seen in USP-controlled room temperature. The manufacturer is ABolco, which is distributed in the USA by Soloo Healthcare. The Patient Information should always be provided separately to the patient.*

This document appears to be a table that lists the effects of various drugs on the pharmacokinetics of tadalafil, a medication used to treat erectile dysfunction. The table shows fold changes and 90% confidence intervals for key measures of tadalafil's effectiveness when taken with drugs that inhibit or induce the CYP3A enzyme system, including ritonavir, ketoconazole, and rifampin, as well as the H2 antagonist nizatidine. The table includes both AUC and Cmax measurements for each drug combination.*

This appears to be information related to drug interactions and dosing adjustments. The text mentions different drugs and their impact on certain enzymes and proteins in the body. It also provides recommendations for dose adjustment based on fold change and 90%CI. The chart shows different percentages of change relative to a coadministered drug alone.*